Managing Dry Eye Before Cataract Surgery: A Complete Guide to Treatment Options

Dry eye disease is present in up to 55 percent of patients presenting for cataract surgery and is the most important modifiable factor affecting the accuracy of preoperative biometry and IOL power calculation. An unstable or irregular tear film distorts the corneal surface measurements used to calculate the power of the intraocular lens, leading to a higher risk of refractive surprise after surgery. Treating dry eye before biometry and before surgery improves measurement accuracy, reduces postoperative symptoms, and optimises the performance of premium lens implants. This guide covers the full spectrum of dry eye management options from the simplest first-line treatments through to advanced in-clinic interventions, and how each is used in the context of cataract surgery preparation. For a broader guide to cataract surgery in Melbourne including what to expect from the pre-operative assessment, see our companion overview. For patients with glaucoma, see the detailed discussion of dry eye from glaucoma drops and its impact on biometry.

Why treating dry eye before cataract surgery matters

Dry eye disease in cataract surgery patients is not simply a comfort issue. It has direct clinical consequences for surgical planning and outcomes that make preoperative treatment a clinical priority rather than an optional enhancement.

The mechanism is straightforward. Modern optical biometers measure corneal curvature by analysing the reflection of light from the anterior corneal surface. The anterior corneal surface is coated by the tear film. When the tear film is unstable or irregular, the reflected image is distorted and the keratometry measurements are inaccurate. Inaccurate keratometry produces errors in IOL power calculation that cannot be corrected by choosing a better formula. The error is in the measurement input, not the calculation method.

A 2024 study published in PMC found that patients with dry eye disease showed significantly greater keratometry variability between repeated measurements compared with controls, and that four weeks of lipid-containing tear treatment significantly improved keratometric stability and changed the predicted IOL power in a clinically meaningful proportion of patients (PMC12843478). This study directly demonstrates that treating dry eye before biometry produces more accurate measurements.

For toric IOL planning, dry eye has compounded consequences. Toric IOL power and axis calculation depend on both the magnitude and the axis of corneal astigmatism. An unstable tear film produces variable axis readings as well as variable magnitude readings, increasing the risk of toric IOL misalignment and residual postoperative astigmatism. This makes ocular surface optimisation particularly important for patients considering premium IOL options and the importance of ocular surface optimisation.

Cataract surgery itself reliably worsens dry eye postoperatively through corneal nerve transection, goblet cell loss, and the preservative toxicity of postoperative antibiotic and steroid drops. Patients who have pre-existing dry eye consistently experience worsening symptoms after surgery. Optimising the ocular surface before surgery provides a better starting point for the inevitable postoperative dry eye phase and produces better subjective outcomes with premium lens implants. For guidance on the recovery period, see our guide to cataract surgery recovery and managing postoperative dry eye.

Step one: warm compresses

Warm compresses are the foundation of meibomian gland dysfunction treatment and the most effective first step for most dry eye patients preparing for cataract surgery. Applied consistently for at least four minutes, adequate heat liquefies the inspissated meibum that blocks the gland orifices, allowing the lipid layer of the tear film to be restored.

The meibomian glands in the eyelids produce the lipid layer of the tear film that prevents evaporation. In MGD, the meibum becomes inspissated and viscous, blocking the gland orifices and preventing adequate lipid secretion. Applying heat to the eyelids liquefies the inspissated meibum and allows it to flow freely from the glands.

The evidence base for warm compresses in MGD is well-established. The TFOS DEWS II report, the most comprehensive international consensus document on dry eye disease, endorses warm compresses as a core first-line treatment for evaporative dry eye from MGD. Studies have shown that warming the eyelid to at least 40 degrees Celsius for a minimum of four minutes is required to achieve adequate melting of meibum. A 2020 systematic review of 30 studies found that eyelid warming produced significant improvements in non-invasive tear break-up time, meibomian gland scores, and ocular surface staining in patients with MGD.

How to perform warm compresses correctly:

The key principle is sustained, adequate heat delivery. A flannel cloth soaked in very warm water is the simplest method but loses heat rapidly. Dedicated reusable eye masks such as the Eyegiene Insta-Warm mask or MGDRx EyeBag are heated in a microwave for approximately 30 seconds and maintain therapeutic temperature for the four to ten minutes of application. These are more effective than a flannel alone because they maintain heat throughout the treatment period.

Apply the warm compress to closed eyelids for a minimum of four to five minutes, pressing gently. After warming, immediately perform gentle lid massage by rolling the fingertip from the base of the eyelashes toward the lid margin to express the now-liquefied meibum from the gland orifices. This expression step is important: warming without expression simply heats the meibum without necessarily clearing it from the glands.

The recommended frequency before cataract surgery is once to twice daily. Consistent daily use for at least four to six weeks before biometry produces the most reliable improvement in meibomian gland function and tear film stability.

Step two: lid hygiene and lid scrubs

Lid hygiene removes the bacterial biofilm, Demodex mites, and seborrheic debris that accumulate at the eyelid margin and contribute to gland obstruction and lid margin inflammation. It is performed after warm compresses, when the meibum has been softened and expressed.

Lid scrubs are performed after warm compresses, when the meibum has been softened and expressed.

Commercial lid scrub preparations include pre-moistened wipes such as Blephaclean, Blephagel, and Sterilid, which contain surfactants that dissolve the lipid debris and biofilm at the lid margin, and antimicrobial agents that reduce the bacterial load. These are more effective and more convenient than diluted baby shampoo, which has been used historically but is not specifically formulated for the eyelid margin and can cause irritation.

HOCL (hypochlorous acid) lid cleansing sprays such as Avenova and Blephasol are an effective alternative to scrub wipes. Hypochlorous acid is a naturally occurring antimicrobial produced by the immune system that breaks down bacterial biofilm, eliminates Demodex mites, and reduces eyelid margin inflammation without causing the irritation associated with detergent-based scrubs. A 2018 prospective study found that 0.01 percent hypochlorous acid solution significantly improved ocular surface disease index scores, eyelid margin scores, and Demodex counts in patients with MGD and blepharitis.

How to perform lid scrubs correctly:

Using a commercially prepared lid scrub wipe or a cotton bud moistened with Blephagel or HOCL solution, gently scrub along the base of the eyelashes on both upper and lower lids in a horizontal motion. The goal is to remove the crusting, debris, and biofilm that accumulates at the lid margin without abrading the delicate lid margin skin. Rinse with clean water afterward if using a detergent-based product.

Frequency before cataract surgery is once daily in the morning, performed after warm compresses.

Step three: preservative-free artificial tears

Preservative-free lubricating drops are the preferred formulation for all patients with dry eye preparing for cataract surgery. Drops containing benzalkonium chloride add toxicity to the corneal epithelium and goblet cells, worsening the condition being treated and compounding any existing damage from preserved glaucoma medications.

Why preservative-free drops are essential for cataract surgery patients:

Preserved lubricating drops contain benzalkonium chloride (BAK) or alternative preservatives such as polyquad or sofZia. As discussed in relation to dry eye from glaucoma drops, BAK is toxic to the corneal epithelium and goblet cells with chronic use. For a patient using preserved drops multiple times daily in the weeks before cataract surgery, the BAK exposure adds to any existing ocular surface toxicity from glaucoma drops or other preserved medications, worsening the very condition being treated.

Preservative-free artificial tears are dispensed in single-use vials or in multi-dose bottles with preservative-free delivery systems (such as the ABAK or COMOD systems used by Thea Pharmaceuticals products). Single-use vials are preferable for patients using drops more than four times daily.

Formulations and what they contain:

Sodium hyaluronate (hyaluronic acid) drops such as HyloFresh, Hylotears, Blink Intensive Tears, and Systane Hydration are the most widely used lubricating drops for dry eye in Australia. Hyaluronate is a naturally occurring glycosaminoglycan with viscoelastic properties that coats and protects the corneal surface, promotes epithelial healing, and has a longer residence time on the ocular surface than simple saline or methylcellulose drops. A 2019 systematic review published in Eye confirmed that sodium hyaluronate drops significantly improved tear break-up time, corneal staining, and subjective symptoms compared with saline controls in MGD patients.

Lipid-containing drops such as Systane Complete, Blink Total Comfort, and Emustil address both the aqueous and the lipid layer of the tear film. These drops contain phospholipid emulsions or mineral oil formulations that supplement the deficient lipid layer in evaporative dry eye from MGD. A clinical study specifically evaluating lipid-containing drops before cataract surgery found that four weeks of treatment significantly stabilised keratometry measurements and changed the predicted IOL power in a clinically meaningful proportion of patients (PMC12843478). Lipid-containing drops are the preferred formulation for patients with MGD-related dry eye preparing for cataract surgery.

Carbomer gel drops such as Viscotears and Refresh Liquigel provide longer contact time and are useful for overnight use or for patients with severe aqueous deficiency, but are not suitable for use immediately before biometry measurements as they temporarily distort the tear film.

Frequency before cataract surgery: preservative-free lubricating drops should be used at minimum four times daily and ideally six to eight times daily in patients with significant dry eye in the weeks before biometry. More frequent application maintains better tear film stability throughout the day.

Step four: omega-3 supplementation

Oral omega-3 supplementation with EPA and DHA provides anti-inflammatory benefit to meibomian gland function over six to twelve weeks and is a low-risk adjunct to the warm compress, lid hygiene, and artificial tear regimen.

Oral omega-3 fatty acid supplementation, specifically the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has a biologically plausible mechanism for benefiting MGD-related dry eye through their anti-inflammatory effects on meibomian gland secretion and eicosanoid metabolism.

The evidence for omega-3 in dry eye is more mixed than for warm compresses and lid hygiene, but a meaningful body of evidence supports its use as an adjunct treatment. A 2019 prospective randomised study published in the Asia Pacific Journal of Ophthalmology found significant improvements in OSDI scores, tear break-up time, and meibomian gland secretion quality in patients taking 1.5 grams of EPA plus DHA daily for three months compared with a control group. The DREAM trial, a large multicentre randomised controlled trial of omega-3 supplementation in dry eye published in the New England Journal of Medicine in 2018, found no statistically significant benefit of omega-3 over refined olive oil placebo on the primary outcome measure, but has been criticised for the high omega-3 content of the olive oil placebo and the ceiling effect on the primary outcome scale.

For patients preparing for cataract surgery, omega-3 supplementation with EPA and DHA at doses of 1.5 to 3.0 grams daily is a reasonable adjunct to the warm compress, lid hygiene, and artificial tear regimen. It is safe, well-tolerated, and has the potential to provide additional anti-inflammatory benefit to meibomian gland function over six to twelve weeks. Fish oil supplements or algal omega-3 preparations are appropriate sources. Re-esterified triglyceride forms have better bioavailability than ethyl ester forms.

Step five: in-office meibomian gland expression

In-office meibomian gland expression applies controlled mechanical pressure to the tarsal plate to clear gland obstructions that cannot be cleared by home massage alone. It is most appropriate for patients with moderate to severe MGD and is often combined with LLLT or IPL as part of a clinic-based dry eye management programme before cataract surgery.

Meibomian gland expression (MGX) is the manual expression of inspissated meibum from the gland orifices, performed in the clinic after warming. It is more effective than home warm compresses alone because the clinician can apply controlled pressure to the tarsal plate to mechanically clear gland obstructions that cannot be cleared by home massage alone.

MGX is typically performed using a dedicated expression device such as the Mastrota paddle or a cotton bud applied to the inner lid margin, with gentle but firm sustained pressure. The procedure takes five to ten minutes and is performed after a warming step in the clinic. It can be somewhat uncomfortable but is well-tolerated by most patients when performed gently with adequate topical anaesthetic.

In-office MGX is most appropriate for patients with moderate to severe MGD where home treatments have not produced adequate improvement, and is often combined with LLLT or IPL treatments as part of a clinic-based dry eye management programme before cataract surgery.

Advanced in-clinic options: LLLT and IPL

LLLT and IPL produce clinically superior improvements in meibomian gland function compared with home-based treatments alone and are the appropriate next step for patients with moderate to severe MGD who do not respond to four to six weeks of first-line therapy, or those who need more rapid ocular surface optimisation before a planned surgical date.

For patients with moderate to severe MGD who do not respond adequately to home-based first-line treatments in the four to six week timeframe before cataract surgery, or for patients in whom more rapid and complete ocular surface optimisation is needed, LLLT and IPL offer clinically proven benefits that exceed what is achievable with home treatments alone.

LLLT uses near-infrared light to stimulate meibomian gland function through photobiomodulation of the gland acinar cells. A 2024 randomised controlled trial published in the British Journal of Ophthalmology found that two sessions of LLLT performed before and after cataract surgery improved tear film stability and reduced postoperative dry eye symptoms compared with controls.

IPL uses pulsed light to photocoagulate abnormal lid margin vasculature, reduce inflammatory mediators, and thermally warm the meibomian glands. Multiple randomised trials have demonstrated significant improvements in tear break-up time, meibomian gland scores, and symptom scores after three to four sessions at two-week intervals.

For a detailed discussion of the evidence for LLLT and IPL, treatment protocols, the timing of treatments relative to biometry and surgery, and when repeat sessions are needed, see the dedicated guide to LLLT and IPL for dry eye treatment before cataract surgery.

The treatment sequence and timeline before cataract surgery

The recommended approach follows a stepped protocol based on severity, with the minimum timeline from initiating treatment to biometry being four weeks for mild cases and eight to twelve weeks for moderate to severe cases requiring LLLT or IPL.

For mild dry eye: initiate preservative-free lubricating drops (lipid-containing formulation) four to six times daily. Add warm compresses once daily. Add omega-3 supplementation. Repeat biometry after four weeks of consistent treatment. If keratometry measurements are stable and reproducible, proceed with surgical planning.

For moderate dry eye: all of the above plus daily lid scrubs with a commercial lid hygiene preparation. Consider in-office MGX at the pre-operative assessment. Consider LLLT or IPL if four weeks of home treatment is insufficient to stabilise keratometry measurements. Repeat biometry after four to six weeks of treatment. Target measurements that show reproducibility within 0.25 dioptres on keratometry before proceeding.

For severe dry eye or patients with significant MGD on multiple preserved medications: prioritise switching preserved medications to preservative-free formulations. Initiate full home-based regimen and schedule LLLT or IPL treatment course. Delay biometry until after completing the initial treatment course and allowing four weeks for the ocular surface to stabilise. Repeat biometry at two separate visits and compare for consistency before confirming IOL selection.

The minimum timeline from initiating dry eye treatment to biometry is four weeks for mild cases and eight to twelve weeks for moderate to severe cases requiring LLLT or IPL.

Postoperative dry eye management

Cataract surgery worsens dry eye in the first one to three months postoperatively through corneal nerve transection, goblet cell loss, and preserved postoperative drops. Patients should be prepared for this and counselled to continue their dry eye management regimen throughout the postoperative period.

Cataract surgery worsens dry eye through corneal nerve transection, goblet cell loss from surgical irrigation, and the preservative toxicity of postoperative antibiotic and steroid drops. Patients should be counselled that dry eye symptoms may worsen in the first one to three months after surgery before improving as corneal nerves regenerate over six to twelve months.

Postoperative dry eye management includes continuing preservative-free lubricating drops frequently throughout the day for at least three to six months. Patients who were using warm compresses and lid hygiene before surgery should continue these through the postoperative period. For patients with premium diffractive lens implants, postoperative dry eye management is particularly important because the optical performance of diffractive lenses is directly dependent on tear film quality.

Referral guidance for optometrists

Optometrists identifying dry eye before cataract referral help the surgical team plan treatment timing and avoid scheduling biometry before the tear film is stable. The following patients should have dry eye specifically assessed and documented before referral.

Patients with known dry eye disease, blepharitis, or rosacea. Patients on long-term preserved glaucoma drops. Patients with a history of LASIK or PRK. Patients with dry eye in diabetic patients. Patients with irregular or variable keratometry or topography readings that are inconsistent with the measured refraction.

The single most useful piece of information to include in a referral where dry eye is suspected is whether the corneal topography showed consistent and reproducible readings, or whether variability was observed suggesting an unstable tear film.

For more information on referral criteria and what to include in a referral, see the referral information for optometrists page.

Arranging an assessment

If you have dry eye disease and are preparing for cataract surgery, a preoperative assessment that includes comprehensive ocular surface evaluation alongside biometry planning is the most important step in ensuring an accurate and successful surgical outcome.

I consult at Northern Eye Consultants, Northpark Private Hospital, Bundoora, and at Bass Coast Eye Centre, Wonthaggi. A referral from your GP or optometrist is required.

Contact Northern Eye Consultants to arrange an assessment. For referral information for GPs and optometrists, visit the Northern Eye Consultants for-referrers page. Further information on cataract surgery Melbourne including a published five-year surgical outcomes audit is available at drmacintyre.com.

References

1. Impact of Dry Eye Disease and Lipid-Containing Artificial Tears on Keratometric Reproducibility and IOL Calculation. PMC12843478. https://pmc.ncbi.nlm.nih.gov/articles/PMC12843478/
2. TFOS DEWS II Management and Therapy Report. Ocular Surface. 2017;15(3):575-628. https://www.tfosdewsreport.org/management_and_therapy/en/
3. Sodium Hyaluronate eye drops in the treatment of dry eye. Eye. 2019. https://www.nature.com/articles/s41433-018-0319-6
4. Giannaccare G, et al. Outcomes of LLLT before and after cataract surgery for the prophylaxis of postoperative dry eye. Br J Ophthalmol. 2024;108(8):1172-1176. https://pubmed.ncbi.nlm.nih.gov/37890879/
5. Mechanisms and management of dry eye in cataract surgery patients. PubMed 26569526. https://pubmed.ncbi.nlm.nih.gov/26569526/
6. Kolko M, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocular Surface. 2023;29:456-468. https://pubmed.ncbi.nlm.nih.gov/37302545/
7. Dry Eye Workshop II. Management and Therapy. The Ocular Surface. 2017. https://www.sciencedirect.com/science/article/pii/S1542012417300721
8. Nibandhe AS, Donthineni PR. Understanding and Optimizing Ocular Biometry for Cataract Surgery in Dry Eye Disease. Semin Ophthalmol. 2023;38(1):24-30. https://pubmed.ncbi.nlm.nih.gov/35989638/